Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Debt / NOTE 2.250% 3/0
-
Market price (% of par)
-
112.88%
-
Total 13F principal
-
$272,401,354
-
Principal change
-
-$7,263,624
-
Total reported market value
-
$307,917,277
-
Number of holders
-
29
-
Value change
-
+$569,601
-
Number of buys
-
13
-
Number of sells
-
14
Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 as of Q3 2025
As of 30 Sep 2025,
TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 was held by
29 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$272,401,354
in principal (par value) of the bond.
The largest 10 bondholders included
Linden Advisors LP, D. E. Shaw & Co., Inc., Graham Capital Management, L.P., ADVENT CAPITAL MANAGEMENT /DE/, MILLENNIUM MANAGEMENT LLC, LORD, ABBETT & CO. LLC, Point72 Asset Management, L.P., OAKTREE CAPITAL MANAGEMENT LP, AGF MANAGEMENT LTD, and Polar Capital Holdings Plc.
This page lists
29
institutional bondholders reporting positions
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.